Minerva gastroenterology最新文献_第2页

Switching rate from intravenous to subcutaneous vedolizumab in managing inflammatory bowel diseases is lower than expected. 在治疗炎症性肠病时，从静脉注射到皮下注射维多珠单抗的转换率低于预期。

IF 1.9

Minerva gastroenterology Pub Date : 2025-03-01 Epub Date: 2024-10-29 DOI: 10.23736/S2724-5985.24.03712-4

Antonio Tursi, Giammarco Mocci, Walter Elisei, Edoardo Savarino, Giovanni Maconi, Franco Scaldaferri, Alfredo Papa

{"title":"Switching rate from intravenous to subcutaneous vedolizumab in managing inflammatory bowel diseases is lower than expected.","authors":"Antonio Tursi, Giammarco Mocci, Walter Elisei, Edoardo Savarino, Giovanni Maconi, Franco Scaldaferri, Alfredo Papa","doi":"10.23736/S2724-5985.24.03712-4","DOIUrl":"10.23736/S2724-5985.24.03712-4","url":null,"abstract":"Background: It is known that the subcutaneous (SC) route administration of biologic drugs has several potential benefits for patient and the healthcare system. Since few real-world data are available yet about the rate of transition from intravenous (IV) to SC Vedolizumab (VDZ) in the Italian population, we assessed this rate in a large cohort of inflammatory bowel disease (IBD) patients under remission receiving IV VDZ as standard of care in a real-world setting.Methods: Searching who was asked to switch from IV VDZ To SC VDZ, and assessing the rate of acceptance. The Mayo score in Ulcerative colitis (UC) and the Harvey-Bradshaw Index (HBI) in Crohn's Disease (CD) scored the clinical activity. Achievement and maintenance of clinical remission during the follow-up, and safety were the primary endpoints.Results: Overall, 238 patients (145 with UC and 93 with CD) having remission ≥1 year with VDZ were asked to switch to VDZ SC, but only nine patients (four with UC and five with CD, 3.78% of the total population to which the switch was proposed) agreed to switch. No difference were found between patients accepting and patients refusing switching about the reasons of the choice. All patients accepting switch maintained clinical remission during the follow-up, and no adverse events were recorded.Conclusions: Switching to SC route is a safe and effective choice for IBD patients under remission using VDZ. However, this choice is not preferred by the majority of patients on stable remission under IV VDZ.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":"15-21"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Driving scientific progress and shaping the future of gastroenterology: a new start for our Journal, between innovation, growth and multidisciplinarity. 推动科学进步，塑造胃肠病学的未来：我们杂志在创新，增长和多学科之间的新起点。

IF 1.9

Minerva gastroenterology Pub Date : 2025-03-01 DOI: 10.23736/S2724-5985.25.03940-3

Loris R Lopetuso, Franco Scaldaferri

引用次数: 0

Small intestinal bacterial overgrowth: from malabsorption to misinterpretation. 小肠细菌过度生长：从吸收不良到误读。

IF 1.9

Minerva gastroenterology Pub Date : 2025-03-01 Epub Date: 2025-01-13 DOI: 10.23736/S2724-5985.24.03781-1

Eamonn M Quigley

{"title":"Small intestinal bacterial overgrowth: from malabsorption to misinterpretation.","authors":"Eamonn M Quigley","doi":"10.23736/S2724-5985.24.03781-1","DOIUrl":"10.23736/S2724-5985.24.03781-1","url":null,"abstract":"Small intestinal bacterial overgrowth (SIBO) was originally described as a cause of maldigestion and malabsorption in situations where disruptions of intestinal anatomy or physiology favored the proliferation of bacteria normally confined to the colon. In this context, the pathogenesis of symptoms resulting from SIBO was well described. More recently, the concept of SIBO was extended to explain symptoms such as bloating, altered bowel habit and discomfort among individuals with irritable bowel syndrome and since then a whole host of gastrointestinal and extragastrointestinal disorders have been attributed to SIBO. In these more recent studies, the diagnosis of SIBO has been largely based on breath hydrogen testing; an approach that is subjected to misinterpretation. Here we critically assess the \"modern\" (as against the \"classical\") concept of SIBO and plead for caution in the application of breath tests, and those that employ lactulose as the substrate, in particular, to the diagnosis of this disorder. We look forward to the application of modern molecular microbiological techniques to the assessment of the small intestinal microbiome and metabolome and the delineation of what is truly normal.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":"65-73"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142974114","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Robuvit® supplementation reduces progression of non-alcoholic fatty liver disease in elderly subjects. 罗布维特®补充剂可减少老年人非酒精性脂肪肝疾病的进展。

IF 1.9

Minerva gastroenterology Pub Date : 2025-03-01 Epub Date: 2024-12-04 DOI: 10.23736/S2724-5985.24.03787-2

Maria R Cesarone, Gianni Belcaro, David Cox, Giuseppe Gizzi, Luciano Pellegrini, Claudia Scipione, Valeria Scipione, Francesca Coppazuccari, Mark Dugall, Shu Hu, Luciano Orsini, Marcello Corsi, Beatrice Feragalli, Roberto Cotellese

引用次数: 0

Pancreatic necrosis: a scoping review. 胰腺坏死：范围综述。

IF 1.9

Minerva gastroenterology Pub Date : 2025-03-01 Epub Date: 2024-10-31 DOI: 10.23736/S2724-5985.24.03658-1

Anthony Rainho, Mira Sridharan, Daniel S Strand

{"title":"Pancreatic necrosis: a scoping review.","authors":"Anthony Rainho, Mira Sridharan, Daniel S Strand","doi":"10.23736/S2724-5985.24.03658-1","DOIUrl":"10.23736/S2724-5985.24.03658-1","url":null,"abstract":"Acute pancreatitis (AP) is a commonly encountered GI diagnosis, accounting for 275,000 hospital admissions annually in the United States alone. Pancreatic necrosis (PN) is the most common complication of AP, and the development of PN is associated with significant morbidity and increased mortality. This expert review evaluates the evidence-based management of symptomatic PN from the era of maximal open pancreatic necrosectomy in the late 1990s though the modern paradigm of minimally invasive and endoscopic interventions. The authors present the retrospective and controlled data behind the \"step-up approach\" to PN treatment and discuss the application of current society guidance. Evidence based management of PN is characterized by early supportive care, and treatment by minimally invasive intervention when a patient is critically ill or persistently symptomatic. Appropriate choices when intervention is required include percutaneous drainage, minimally invasive surgery, and/or endoscopic treatment. The transition from open maximal necrosectomy to minimally invasive intervention has resulted in improved outcomes for patients, including gains in mortality, significant morbidity, and cost. The ideal precision management strategy for an individual patient remains an area of increasing understanding.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":"48-64"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142549865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can dysmetabolic comorbidities carry hepatic fat accumulation in patients with inflammatory bowel diseases? 代谢紊乱合并症会导致炎症性肠病患者肝脏脂肪堆积吗？

IF 1.9

Minerva gastroenterology Pub Date : 2025-03-01 Epub Date: 2024-01-19 DOI: 10.23736/S2724-5985.23.03617-3

Ludovico Abenavoli, Giuseppe Gm Scarlata, Rocco Spagnuolo, Francesco Luzza

引用次数: 0

Liver fibrosis evaluation in lean steatotic liver disease patients. 瘦脂肪肝患者的肝纤维化评估

IF 1.9

Minerva gastroenterology Pub Date : 2025-03-01 Epub Date: 2024-05-14 DOI: 10.23736/S2724-5985.24.03686-6

Gianni Testino

引用次数: 0

Research progress of MicroRNA and its signaling pathways in gastric cancer. 胃癌 MicroRNA 及其信号通路的研究进展。

IF 1.9

Minerva gastroenterology Pub Date : 2025-03-01 Epub Date: 2024-05-14 DOI: 10.23736/S2724-5985.24.03682-9

Xiaojuan Jiang, Furong Wang, Peiwu Li

引用次数: 0

Monitoring the psychopathological profile of inflammatory bowel disease patients treated with biological agents: a pilot study. 监测接受生物制剂治疗的炎症性肠病患者的心理病理特征：一项试点研究。

IF 1.9

Minerva gastroenterology Pub Date : 2025-03-01 Epub Date: 2024-09-18 DOI: 10.23736/S2724-5985.24.03719-7

Antonio M D'Onofrio, Lodovico M Balzoni, Gaspare F Ferrajoli, Federica DI Vincenzo, Daniele Napolitano, Elisa Schiavoni, Georgios D Kotzalidis, Alessio Simonetti, Marianna Mazza, Ilenia Rosa, Mauro Pettorruso, Gabriele Sani, Antonio Gasbarrini, Franco Scaldaferri, Giovanni Camardese

{"title":"Monitoring the psychopathological profile of inflammatory bowel disease patients treated with biological agents: a pilot study.","authors":"Antonio M D'Onofrio, Lodovico M Balzoni, Gaspare F Ferrajoli, Federica DI Vincenzo, Daniele Napolitano, Elisa Schiavoni, Georgios D Kotzalidis, Alessio Simonetti, Marianna Mazza, Ilenia Rosa, Mauro Pettorruso, Gabriele Sani, Antonio Gasbarrini, Franco Scaldaferri, Giovanni Camardese","doi":"10.23736/S2724-5985.24.03719-7","DOIUrl":"10.23736/S2724-5985.24.03719-7","url":null,"abstract":"Background: Biological agents were found to alter the psychopathological profile of a small subgroup of patients treated for a variety of conditions, including inflammatory bowel disease (IBD) and psychiatric disorders. The association between the administration of biological agents and psychopathology needs to be further investigated.Methods: In this naturalistic prospective cohort study, patients with IBD were assigned to two treatment groups, i.e., a biological agent (which also included tofacitinib) or conventional therapy. Clinician-administered scales were used to assess psychosomatic symptoms (Hamilton Depression Rating Scale [Ham-D], Hamilton Anxiety Rating Scale [Ham-A], Young Mania Rating Scale [YMRS], and Brief Psychiatric Rating Scale [BPRS]) and disease activity (Mayo Score and Harvey-Bradshaw Index [HBI]) at baseline, after one, three, and six months of treatment. Each group was assessed for the course of their scores during the observation period at each assessment point.Results: Patients on biological drugs who completed three months of treatment (N.=32) and six months of treatment (N.=20) scored significantly lower on the Mayo compared to baseline. Patients on conventional treatment obtained significant drops from baseline on the HBI after one and three months of treatment (N.=30) and also at the six-month endpoint (N.=11). Both groups showed no improvement or worsening on the psychiatric rating scales.Conclusions: In this study, we found no evidence of psychiatric symptom worsening, as some literature would suggest. Our data suggest that the use of biological agents in IBD is safe.","PeriodicalId":94142,"journal":{"name":"Minerva gastroenterology","volume":" ","pages":"22-32"},"PeriodicalIF":1.9,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142305044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advanced approaches in the comprehensive management of gastroparesis: from etiology to emerging therapies. 胃轻瘫综合治疗的先进方法：从病因学到新兴疗法。

IF 1.9

Minerva gastroenterology Pub Date : 2025-02-27 DOI: 10.23736/S2724-5985.24.03804-X

Vishali Moond, Sahib Singh, Umar Hayat, Parth Patel, Archit Garg, Hassam Ali, Douglas G Adler

引用次数: 0